G ene transfer may offer a new treatment option for cardiovascular diseases. 1 Experimental studies have demonstrated successful arterial gene transfer by using several genes and vectors, [1] [2] [3] [4] [5] [6] [7] and phase I/II trials in patients with severe vascular diseases using different therapeutic genes (VEGF, FGF, E2F decoy) have been reported. 8 -14 
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Optimization of angioplasty procedure and the use of stents have reduced the frequency of restenosis. 15 Recent experiments with drug-coated stents have further improved the success of angioplasty. 16 Still, there is evidence of increased cell proliferation, macrophage infiltration, and even neovascularization in the stented arterial segments. 17 Local gene therapy is an option that might be used to treat both restenosis/in-stent restenosis and myocardial ischemia. 1, 4 Vascular endothelial growth factor (VEGF) accelerates endothelial repair by stimulating endothelial cell migration and proliferation. 18 In addition to having several cytoprotective properties, it induces angiogenesis, especially in ischemic tissues. 1, 5 Adenoviruses have shown their potential in vascular gene transfer. 8, 10 Liposomes may be safer than adenoviruses, 9 but their gene transfer efficiency is clearly lower than that of adenoviruses. 3 In this study, we examined the safety and feasibility of VEGF-Adv and VEGF-P/L gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of myocardial ischemia.
Methods

Patient Selection
This study was performed in two cardiology centers at Kuopio and Helsinki University Hospitals. The trial was approved by ethics committees of the Universities of Kuopio and Helsinki, the Finnish Board for Gene Technology, and the Finnish Agency for Medicinal Products. Informed consent was obtained from all patients. The patients were treated in a double-blind manner and were randomly assigned to 3 study groups in blocks of 9 patients. Inclusion criteria for catheter-based intracoronary gene transfer were age 38 to 75 years (no women of childbearing age), stable Canadian Cardiovascular Society class II to III angina, 60% to 99% diameter stenosis in 1 to 2 of the main coronary arteries in coronary angiography suitable for catheter-based revascularization, diameter of the target vessel 2.5 to 4.0 mm, no previous PTCA of the target vessel, and no contraindications for acetosalicylic acid or heparin. Subjects were excluded if they had diffuse coronary disease, ostial lesions, complex anatomy of the coronary arteries, lesions at bifurcations, length of stenosis Ͼ20 mm, acute myocardial infarction, unstable angina, acute upper respiratory tract infection, diabetes, or malignancy.
End Points
The primary end points were the minimal lumen diameter and percent diameter stenosis measured by quantitative coronary angiography (QCA) at 6-month follow-up. Secondary end points were myocardial perfusion, exercise tolerance, incidence of new cardiac events, emergency or elective angiography or revascularization, functional class, working ability, and need for peroral nitrates at 6-month follow-up. Safety of the local catheter-mediated VEGF gene transfer was also assessed.
PTCA and Gene Transfer
PTCA and stenting were performed according to standard clinical practice, using the femoral approach. Arterial gene transfer was performed at the site of PTCA immediately after the angioplasty but before stent implantation, using an infusion-perfusion catheter (Dispatch catheter; Boston Scientific). 9 All patients received aspirin and heparin. Patients receiving stents were prescribed ticlodipine or clopidogrel.
Adenoviruses and Plasmid/Liposomes
Human clinical grade E1-partial, E3-deleted, first-generation adenoviruses were used in this study. 8, 10 Adenoviruses containing a CMV-hVEGF 165 expression cassette were produced under GMP in 293 cells as described. 10 Adenoviruses were analyzed for the absence of replication-competent viruses by means of a cytopathic effect assay on A549 cells. 8, 19 Virus titers were determined by optical density at 260 nm (P:I ratio Ͻ35), and viral preparations were analyzed to be free of any microbiological or endotoxin contamination (Ͻ20 EU/dose, Whittaker). P/L complexes were prepared as follows: 2000 g pCMV-hVEGF 165 (1 mg/mL; GenBank AB021221) plasmid was complexed with 2000 L of DOTM-A:DOPE (1 mg/mL; 1:1; Valentis Inc) and diluted with 1000 L Ringer's solution. 9, 10 Plasmids used for the study were manufactured under GMP and analyzed to be free of any microbiological or endotoxin contamination (Ͻ200 EU/dose) as described. 9, 10 Thirtyseven patients received VEGF-Adv, 28 patients received VEGF-P/L, and 38 control patients received Ringer's lactate. Some patients were lost from the study after random assignment because of acute respiratory infections before the PTCA procedure, out-ofspecification properties of the final P/L formulation, or interruption of the follow-up.
QCA Analysis
Coronary angiography of the target vessel was performed with standard techniques before PTCA, immediately after the gene transfer and stenting, and at the 6-month follow-up with prior intracoronary injection of nitroglycerin. QCA was performed with the use of the Cardiovascular Measurement System (version 3.0, Medis), as described. 20 All QCA analyses were performed by a single observer, who was blinded to all clinical information.
Exercise Test and Myocardial Perfusion Imaging
A maximal symptom-limited exercise test was performed for a subgroup of patients with the use of a bicycle ergometer, with a protocol of 20 W as an initial workload with increments of 20 W/min, as described. 21 Cardiac SPECT imaging was performed with 99m Tc-sestamibi before and 6 months after the gene transfer with prior adenosine infusion (0.14 mg/kg per minute). 22 Visual interpretation was performed with short-axis, vertical, and horizontal longaxis tomograms divided into 20 segments for each study. Segments were scored at rest and stress by consensus of two experienced observers using a 5-point scoring system (0ϭnormal; 1ϭequivocal; 2ϭmoderate; 3ϭsevere reduction; 4ϭabsence of uptake). The final result was expressed as a ⌬score (perfusion score at rest minus perfusion score during adenosine infusion), which indicates the severity of myocardial ischemia. 22 The observers were blinded for clinical findings, treatment groups, and time of the analysis.
Safety Analyses
Patients were followed at the hospital for 48 hours. Clinical chemistry was analyzed at Kuopio University Hospital Central Laboratory according to ISO9002 standards before PTCA and 2, 7, 14, and 35 days and 6 months after the gene transfer. Anti-Adv antibody levels were measured before and 2 weeks after the gene transfer. Serum VEGF and interleukin-6 (IL-6) concentrations were analyzed by means of specific ELISA tests (Quantikine; R&D Systems, DVE00 and D6050) and the presence of transgene in serum and urine by a specific PCR. 10 All patients were sent a questionnaire 14 to 47 months after the gene transfer to evaluate late outcome of the procedure; 92 patients responded to the questionnaire.
Statistical Analysis
The differences between the treatment groups were calculated by means of ANOVA and Bonferroni's modified t test for continuous variables and 2 test for dichotomous variables. Nonparametric Wilcoxon test was used to calculate differences within the study groups (SPSS 9.0 program, SPSS Inc). Results were considered statistically significant at a value of PϽ0.05. The study was powered to detect a 25% difference at a value of Pϭ0.05, with 80% probability at the 6-month follow-up.
Results
Baseline Characteristics
Characteristics of the patients are shown in Table 1 . No significant differences were present among the study groups.
Safety
During mean follow-up of 28 months (range, 14 to 47 months), 1 death was recorded in the VEGF-Adv group (Table 2) . This patient died because of a previously undiagnosed, ruptured aortic aneurysm 20 months after the gene transfer. Two new cancers (malignant glioma and hypernephroma) were diagnosed in the VEGF-P/L group during the long-term follow-up. One patient in the VEGF-Adv group had sarcoidosal granulomas in the eye and parotid gland. Procedural complications occurred in 4 patients. Two patients had a "no flow" phenomenon and cardiac arrest during control angiography. One of these patients acquired aspiratory pneumonia and pseudomembranotic colitis as the result of antibiotic treatment. One control patient had a stroke a few hours after PTCA (Table 2) . These complications were regarded as serious adverse events but not directly related to gene therapy.
Regarding other adverse effects, fever was most frequent in the VEGF-Adv group (Table 2 ). An increase in anti-Adv antibodies was observed in 23 (62%) patients and a transient increase in serum CRP in 20 (54%) patients in the VEGFAdv group. An increase in anti-Adv antibodies in some control patients was probably due to acute respiratory infections. Other laboratory values did not show any major differences except a transient decrease in the platelet count in all study groups and an increase in LDH in the VEGF-Adv patients (Table 3 ). Serum IL-6 level was increased in all study groups 2 days after the gene transfer, and it was highest in the VEGF-Adv group. No increases were detected in serum VEGF levels in the treated groups (Table 3) . No transgene was detected in serum or urine 2 days after the gene transfer.
Procedural Outcome and Clinical Measurements
A stent was implanted in 92 (90%) patients because an optimal result was not achieved with PTCA. There were no significant differences in minimal lumen diameter or percent of luminal stenosis between the study groups before or immediately after the procedure (Table 4 ). The overall clinical restenosis rate was 6%. Three patients in the VEGFAdv group and 3 patients in the control group had clinical restenosis of CCS class II to III angina pectoris during the 6-month follow-up. Three patients in the VEGF-Adv group were treated with coronary bypass operation and 3 patients in the control group with repeated PTCA. Two patients in the control group had acute myocardial infarction (Table 2) . Of the secondary end points, a significant improvement in myocardial perfusion was detected in the VEGF-Adv group after the 6-month follow-up (Figure) . Functional capacity and exercise time in the stress exercise test tended to improve in all study groups ( Figure, b and c) . No statistically significant differences were observed between the study groups in CCS classification, working ability, or in the need of peroral nitrates (Table 5 ).
Discussion
The Kuopio Angiogenesis Trial (KAT) II is the first randomized, double-blind, placebo-controlled trial studying the use of local intracoronary VEGF gene transfer in the treatment of coronary heart disease and prevention of restenosis after coronary angioplasty. VEGF was chosen as the treatment gene because of its properties as an angiogenic, cytoprotective, and endothelium repair factor. 1 Increased NO and prostacyclin secretion induced by VEGF is known to limit smooth muscle cell proliferation and platelet aggregation in animal models. 4, 18 VEGF gene transfer was used instead of recombinant protein administration because gene transfer can We saw transient fever and increases in serum CRP and LDH levels in the VEGF-Adv group. Systemic inflammatory reactions may be caused by a systemic release of the Adv-vector, followed by the production of cytokines in the liver, macrophages, and dendritic cells. It is interesting to note that fever was also detected in some VEGF-P/L patients, which is probably due to the higher level of endotoxin in the GMP-grade plasmids than in the adenoviruses. Liposomes may also contain some peroxidized lipids that may contribute to the transient fever reaction. Increase in the LDH level in the VEGF-Adv group may indicate some liver reactions, although no significant changes were seen in transaminases.
During the mean follow-up of 28 months, 1 death was recorded. This occurred in a VEGF-Adv-treated patient and was due to a rupture of a previously undiagnosed aortic aneurysm. The patient was a 70-year-old man with universal atherosclerosis, and the death was considered to be unrelated to gene therapy. Two new cancers (malignant glioma and hypernephroma) were diagnosed in the VEGF-P/L group during the long-term follow-up. Both malignancies were found more than 2 years after the gene transfer. In the VEGF-Adv group, one patient underwent surgery for sarcoidosis in the eye and parotid gland 2 years after the gene transfer. However, these incidences do not differ from those seen in the general population, since according to Finnish Cancer Register, we could anticipate 0.5 to 1 new cancers per 100 persons per year in the general population of this age group. 25 It is evident that longer follow-up times are needed to determine cancer incidences after the VEGF gene therapy.
In conclusion, results of the current study suggest that catheter-mediated intracoronary gene transfer is safe and well tolerated. The treatment did not affect the incidence of postangioplasty restenosis, but a significant improvement was seen in myocardial perfusion in the VEGF-Adv-treated patients. 
